公开(公告)号：EP2426149A4

公开(公告)日：2013-01-23

申请号：EP10769835

申请日：2010-04-30

申请人： UNIV TOKYO ,  PERSEUS PROTEOMICS INC

发明人： ABURATANI HIROYUKI ,  ZHANG LILIN ,  ISHII KEISUKE ,  KOUDA KATSUSHI ,  SAKAMOTO AYA ,  KATSUMI KEIKO ,  ONISHI HIROSHI ,  KAYUKAWA YOKO

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C12N5/10 ,  C12N15/09

CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/732

公开(公告)号：EP2848686A4

公开(公告)日：2016-01-20

申请号：EP12873679

申请日：2012-04-04

申请人： PERSEUS PROTEOMICS INC

发明人： ISHII KEISUKE ,  MITOMO KATSUYUKI ,  KOUDA KATSUSHI ,  NOMURA FUMIKO ,  KAYUKAWA YOKO ,  MATSUURA TADASHI

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/46 ,  C12P21/08

CPC分类号： A61K47/6855 ,  A61K47/48569 ,  A61K47/6851 ,  A61K47/6879 ,  A61K47/6889 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/565

摘要： It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.

摘要翻译： 本发明的目的是提供一种药物结合物，其包含有效杀死表达CDH3的癌细胞的抗CDH3抗体。 根据本发明，提供了通过将针对CDH3的抗体或其对化学治疗剂具有CDH3结合能力的片段的抗体结合而形成的免疫复合物。

公开(公告)号：EP2957632A4

公开(公告)日：2016-10-05

申请号：EP14751339

申请日：2014-02-14

申请人： PERSEUS PROTEOMICS INC

发明人： ISHII KEISUKE ,  MITOMO KATSUYUKI ,  KOUDA KATSUSHI ,  NOMURA FUMIKO ,  KAYUKAWA YOKO ,  MATSUURA TADASHI

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human º subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.